Oscar Ramos‐Campoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oscar Ramos‐Campoy has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Adrià Tort-Merino
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
5 shared publications - Mircea Balasa
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
5 shared publications - Raquel Sánchez-Valle
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
5 shared publications - Albert Lladó
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
4 shared publications - Guadalupe Fernandez‐Villullas
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
4 shared publications - Jordi Juncà‐Parella
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain
4 shared publications
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Comparison of the diagnostic performance of blood‐based biomarkers using two distinct commercially available assays in a prospective memory clinic cohort
Background: Blood‐based biomarkers have recently emerged as minimally‐invasive, accessible and relatively inexpensive diagnostic and prognostic tools for people with cognitive impairment. Before being routinely implemented in clinical practice, the diagnostic performance of distinct commercially available assays should be studied in real‐world cohorts. We aimed to study and compare the diagnostic accuracy of different plasma biomarkers measured using two different assay platforms in a memory clinic cohort.Method: Participants were selected from a prospective memory clinic cohort; all had Alzheimer’s disease (AD) CSF biomarkers performed. Plasma p‐tau181, GFAP and NfL were measured using Simoa (Quanterix), while plasma p‐tau181, Aβ1‐40 and Aβ1‐42 were quantified using Lumipulse G (Fujirebio). Clinical diagnoses were made according to published criteria, blinded to plasma biomarkers. Aβ status (‐/+) was defined by CSF Aβ concentration using local cutoffs.Result: One hundred and ten participants were included (mean age [standard deviation] 66 [7.8] years, 56% women). Diagnostic categories included 10 cognitively unimpaired controls, 24 with suspected non‐neurodegenerative cause of cognitive impairment (SND), 53 AD, 9 Lewy body disease (LBD, 4 Aβ+) and 14 frontotemporal dementia (FTD, 1 Aβ+).Plasma p‐tau181Quanterix and Aβ1‐42/Aβ1‐40 had the highest diagnostic accuracy (Figure 1) to discriminate between SND and AD (AUC [CI] 0.94 [0.89‐0.99] and 0.94 [0.85‐1]), followed by GFAP (0.93 [0.87‐0.99]), p‐tau181Fujirebio (0.90 [0.82‐0.98]) and Aβ1‐42 (0.71 [0.58‐0.85]). Plasma NfL performed the best to differentiate FTD from SND and AD (AUC 0.95 [0.88‐1] and 0.85 [0.71‐0.99], respectively).For Aβ status discrimination (Figure 2), p‐tau181Quanterix had an AUC [CI] of 0.91 [0.85‐0.96], followed by p‐tau181Fujirebio (0.86 [0.79‐0.93]), Aβ1‐42/Aβ1‐40 (0.85 [0.76‐0.93]) and GFAP (0.84 [0.77‐0.92]) with no statistically significant differences in AUCs. Balanced (Youden index) cut‐offs were calculated to study diagnostic performance, resulting in sensitivities of 79‐83%, specificities of 74‐83% and accuracies of 76‐83%. No combination of plasma biomarkers resulted in a significantly increased discriminative accuracy for Aβ status. All plasma biomarkers were moderately correlated with p‐tau181Quanterix (ρ = 0.40‐0.75, Figure 3).Conclusion: In our cohort, p‐tau181Quanterix, p‐tau181Fujirebio, Aβ1‐42/Aβ1‐40 and GFAP had a high diagnostic performance to discriminate CSF‐defined Aβ status. Plasma NfL identified individuals with FTD. Further studies comparing different plasma biomarkers are needed before implementation in clinical practice.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Open AccessComparison of the diagnostic performance of blood‐based biomarkers using two distinct commercially available assays in a prospective memory clinic cohort
Background: Blood‐based biomarkers have recently emerged as minimally‐invasive, accessible and relatively inexpensive diagnostic and prognostic tools for people with cognitive impairment. Before being routinely implemented in clinical practice, the diagnostic performance of distinct commercially available assays should be studied in real‐world cohorts. We aimed to study and compare the diagnostic accuracy of different plasma biomarkers measured using two different assay platforms in a memory clinic cohort.Method: Participants were selected from a prospective memory clinic cohort; all had Alzheimer’s disease (AD) CSF biomarkers performed. Plasma p‐tau181, GFAP and NfL were measured using Simoa (Quanterix), while plasma p‐tau181, Aβ1‐40 and Aβ1‐42 were quantified using Lumipulse G (Fujirebio). Clinical diagnoses were made according to published criteria, blinded to plasma biomarkers. Aβ status (‐/+) was defined by CSF Aβ concentration using local cutoffs.Result: One hundred and ten participants were included (mean age [standard deviation] 66 [7.8] years, 56% women). Diagnostic categories included 10 cognitively unimpaired controls, 24 with suspected non‐neurodegenerative cause of cognitive impairment (SND), 53 AD, 9 Lewy body disease (LBD, 4 Aβ+) and 14 frontotemporal dementia (FTD, 1 Aβ+).Plasma p‐tau181Quanterix and Aβ1‐42/Aβ1‐40 had the highest diagnostic accuracy (Figure 1) to discriminate between SND and AD (AUC [CI] 0.94 [0.89‐0.99] and 0.94 [0.85‐1]), followed by GFAP (0.93 [0.87‐0.99]), p‐tau181Fujirebio (0.90 [0.82‐0.98]) and Aβ1‐42 (0.71 [0.58‐0.85]). Plasma NfL performed the best to differentiate FTD from SND and AD (AUC 0.95 [0.88‐1] and 0.85 [0.71‐0.99], respectively).For Aβ status discrimination (Figure 2), p‐tau181Quanterix had an AUC [CI] of 0.91 [0.85‐0.96], followed by p‐tau181Fujirebio (0.86 [0.79‐0.93]), Aβ1‐42/Aβ1‐40 (0.85 [0.76‐0.93]) and GFAP (0.84 [0.77‐0.92]) with no statistically significant differences in AUCs. Balanced (Youden index) cut‐offs were calculated to study diagnostic performance, resulting in sensitivities of 79‐83%, specificities of 74‐83% and accuracies of 76‐83%. No combination of plasma biomarkers resulted in a significantly increased discriminative accuracy for Aβ status. All plasma biomarkers were moderately correlated with p‐tau181Quanterix (ρ = 0.40‐0.75, Figure 3).Conclusion: In our cohort, p‐tau181Quanterix, p‐tau181Fujirebio, Aβ1‐42/Aβ1‐40 and GFAP had a high diagnostic performance to discriminate CSF‐defined Aβ status. Plasma NfL identified individuals with FTD. Further studies comparing different plasma biomarkers are needed before implementation in clinical practice.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Hippocampal subfields’ sex differences in EOAD
Background: In healthy ageing, there is evidence of sex differences in vulnerability of hippocampal subfields to volume loss. However, this has not been investigated in early‐onset Alzheimer’s disease (15) and 44 healthy controls (HC; A‐T‐N‐) that underwent lumbar puncture for analysis of AD biomarkers, 3T‐MRI scan and neuropsychological assessment. Hippocampal subfield segmentation was performed using T1‐weighted images and Freesurfer 6.0. Volume was adjusted by intracranial volume. Adjusted linear models were used to analyze differences between EOAD and HC and differences between sexes. We calculated Cohen’s d as a measure of the effect size of volume change by sex, restricted to volume differences between EOAD and HC. In EOAD, we used linear models adjusted by age and education to investigate the association of volume loss with 18 cognition z‐scores. Results were adjusted using Bonferroni correction for multiple comparisons.Result: There were no demographic differences across groups. APOEε4 carriers were higher in EOAD‐female/EOAD‐male than HC‐female. EOAD‐female showed higher T‐Tau and P‐Tau levels than EOAD‐male (all p<0.05; Table1). Comparing EOAD vs. HC, differences were found in volume of all subfields and hippocampus (p0.05). When compared to HC of the same sex, EOAD‐female showed differences in the same regions as the whole sample, while EOAD‐male showed differences in bilateral hippocampal tail and left presubiculum and hippocampus (all p<0.05, Bonferroni corrected, Figure 1). We observed larger effect sizes than in women in these regions, except for left hippocampus (Figure 2).In EOAD, higher volume in left CA2/3 predicted higher memory z‐scores, including free and total learning and delayed total recall (p<0.05 Bonferroni corrected; Figure 3). No associations were found in EOAD‐female nor EOAD‐male.Conclusion: In EOAD, the pattern of volume loss in hippocampal subfields was similar between sexes. However, females showed more marked differences from HC, except for bilateral hippocampal tail and left presubiculum. Further studies are necessary to elucidate the existence of sex differences in EOAD and their implication for cognitive impairment.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Open AccessHippocampal subfields’ sex differences in EOAD
Background: In healthy ageing, there is evidence of sex differences in vulnerability of hippocampal subfields to volume loss. However, this has not been investigated in early‐onset Alzheimer’s disease (15) and 44 healthy controls (HC; A‐T‐N‐) that underwent lumbar puncture for analysis of AD biomarkers, 3T‐MRI scan and neuropsychological assessment. Hippocampal subfield segmentation was performed using T1‐weighted images and Freesurfer 6.0. Volume was adjusted by intracranial volume. Adjusted linear models were used to analyze differences between EOAD and HC and differences between sexes. We calculated Cohen’s d as a measure of the effect size of volume change by sex, restricted to volume differences between EOAD and HC. In EOAD, we used linear models adjusted by age and education to investigate the association of volume loss with 18 cognition z‐scores. Results were adjusted using Bonferroni correction for multiple comparisons.Result: There were no demographic differences across groups. APOEε4 carriers were higher in EOAD‐female/EOAD‐male than HC‐female. EOAD‐female showed higher T‐Tau and P‐Tau levels than EOAD‐male (all p<0.05; Table1). Comparing EOAD vs. HC, differences were found in volume of all subfields and hippocampus (p0.05). When compared to HC of the same sex, EOAD‐female showed differences in the same regions as the whole sample, while EOAD‐male showed differences in bilateral hippocampal tail and left presubiculum and hippocampus (all p<0.05, Bonferroni corrected, Figure 1). We observed larger effect sizes than in women in these regions, except for left hippocampus (Figure 2).In EOAD, higher volume in left CA2/3 predicted higher memory z‐scores, including free and total learning and delayed total recall (p<0.05 Bonferroni corrected; Figure 3). No associations were found in EOAD‐female nor EOAD‐male.Conclusion: In EOAD, the pattern of volume loss in hippocampal subfields was similar between sexes. However, females showed more marked differences from HC, except for bilateral hippocampal tail and left presubiculum. Further studies are necessary to elucidate the existence of sex differences in EOAD and their implication for cognitive impairment.
- 21 February 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (8) , e860-e873
Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort
Background and Objectives Blood-based biomarkers have emerged as minimally invasive options for evaluating cognitive impairment. Most studies to date have assessed them in research cohorts, limiting their generalization to everyday clinical practice. We evaluated their diagnostic performance and clinical applicability in a prospective, real-world, memory clinic cohort. Methods All patients referred with suspected cognitive impairment between July 2019 and June 2021 were prospectively invited to participate. Five plasma biomarkers (tau phosphorylated at threonine 181 [p-tau181], glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL], total tau [t-tau], and ubiquitin C-terminal hydrolase L1 [UCH-L1]) were determined with single-molecule array. Performance was assessed in comparison to clinical diagnosis (blinded to plasma results) and amyloid status (CSF/PET). A group of cognitively unimpaired (CU) controls was also included. Results Three hundred forty-nine participants (mean age 68, SD 8.3 years) and 36 CU controls (mean age 61.7, SD 8.2 years) were included. In the subcohort with available Alzheimer disease (AD) biomarkers (n = 268), plasma p-tau181 and GFAP had a high diagnostic accuracy to differentiate AD from non-neurodegenerative causes (area under the receiver operating characteristic curve 0.94 and 0.92, respectively), with p-tau181 systematically outperforming GFAP. Plasma p-tau181 levels predicted amyloid status (85% sensitivity and specificity) with accurate individual prediction in approximately 60% of the patients. Plasma NfL differentiated frontotemporal dementia (FTD) syndromes from CU (0.90) and non-neurodegenerative causes (0.93), whereas the discriminative capacity with AD and between all neurodegenerative and non-neurodegenerative causes was less accurate. A combination of p-tau181 and NfL identified FTD with 82% sensitivity and 85% specificity and had a negative predictive value for neurodegenerative diagnosis of 86%, ruling out half of the non-neurodegenerative diagnoses. In the subcohort without AD biomarkers, similar results were obtained. T-tau and UCH-L1 did not offer added diagnostic value. Discussion Plasma p-tau181 predicted amyloid status with high accuracy and could have potentially avoided CSF/amyloid PET testing in approximately 60% of subjects in a memory clinic setting. NfL was useful for identifying FTD from non-neurodegenerative causes but behaved worse than p-tau181 in all other comparisons. Combining p-tau181 and NfL improved diagnostic performance for FTD and non-neurodegenerative diagnoses. However, the 14% false-negative results suggest that further improvement is needed before implementation outside memory clinics. Classification of Evidence This study provides Class I evidence that plasma p-tau181 correlates with the presence or absence of AD and a combination of plasma p-tau181 and NfL correlates moderately well with a diagnosis of FTD.
- 21 February 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (8) , e860-e873
Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort
Background and Objectives Blood-based biomarkers have emerged as minimally invasive options for evaluating cognitive impairment. Most studies to date have assessed them in research cohorts, limiting their generalization to everyday clinical practice. We evaluated their diagnostic performance and clinical applicability in a prospective, real-world, memory clinic cohort. Methods All patients referred with suspected cognitive impairment between July 2019 and June 2021 were prospectively invited to participate. Five plasma biomarkers (tau phosphorylated at threonine 181 [p-tau181], glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL], total tau [t-tau], and ubiquitin C-terminal hydrolase L1 [UCH-L1]) were determined with single-molecule array. Performance was assessed in comparison to clinical diagnosis (blinded to plasma results) and amyloid status (CSF/PET). A group of cognitively unimpaired (CU) controls was also included. Results Three hundred forty-nine participants (mean age 68, SD 8.3 years) and 36 CU controls (mean age 61.7, SD 8.2 years) were included. In the subcohort with available Alzheimer disease (AD) biomarkers (n = 268), plasma p-tau181 and GFAP had a high diagnostic accuracy to differentiate AD from non-neurodegenerative causes (area under the receiver operating characteristic curve 0.94 and 0.92, respectively), with p-tau181 systematically outperforming GFAP. Plasma p-tau181 levels predicted amyloid status (85% sensitivity and specificity) with accurate individual prediction in approximately 60% of the patients. Plasma NfL differentiated frontotemporal dementia (FTD) syndromes from CU (0.90) and non-neurodegenerative causes (0.93), whereas the discriminative capacity with AD and between all neurodegenerative and non-neurodegenerative causes was less accurate. A combination of p-tau181 and NfL identified FTD with 82% sensitivity and 85% specificity and had a negative predictive value for neurodegenerative diagnosis of 86%, ruling out half of the non-neurodegenerative diagnoses. In the subcohort without AD biomarkers, similar results were obtained. T-tau and UCH-L1 did not offer added diagnostic value. Discussion Plasma p-tau181 predicted amyloid status with high accuracy and could have potentially avoided CSF/amyloid PET testing in approximately 60% of subjects in a memory clinic setting. NfL was useful for identifying FTD from non-neurodegenerative causes but behaved worse than p-tau181 in all other comparisons. Combining p-tau181 and NfL improved diagnostic performance for FTD and non-neurodegenerative diagnoses. However, the 14% false-negative results suggest that further improvement is needed before implementation outside memory clinics. Classification of Evidence This study provides Class I evidence that plasma p-tau181 correlates with the presence or absence of AD and a combination of plasma p-tau181 and NfL correlates moderately well with a diagnosis of FTD.
- 9 September 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (12) , 3623-3632
Sex differences in early‐onset Alzheimer's disease
Background and purpose: Sex is believed to drive heterogeneity in Alzheimer's disease (AD), although evidence in early‐onset AD (EOAD; <65 years) is scarce.Methods: We included 62 EOAD patients and 44 healthy controls (HCs) with core AD cerebrospinal fluid (CSF) biomarkers, neurofilament light chain levels, neuropsychological assessment, and 3‐T magnetic resonance imaging. We measured cortical thickness (CTh) and hippocampal subfield volumes (HpS) using FreeSurfer. Adjusted linear models were used to analyze sex‐differences and the relationship between atrophy and cognition.Results: Compared to same‐sex HCs, female EOAD subjects showed greater cognitive impairment and broader atrophy burden than male EOAD subjects. In a direct female‐EOAD versus male‐EOAD comparison, there were slight differences in temporal CTh, with no differences in cognition or HpS. CSF tau levels were higher in female EOAD than in male EOAD subjects. Greater atrophy was associated with worse cognition in female EOAD subjects.Conclusions: At diagnosis, there are sex differences in the pattern of cognitive impairment, atrophy burden, and CSF tau in EOAD, suggesting there is an influence of sex on pathology spreading and susceptibility to the disease in EOAD.
- 9 September 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (12) , 3623-3632
Sex differences in early‐onset Alzheimer's disease
Background and purpose: Sex is believed to drive heterogeneity in Alzheimer's disease (AD), although evidence in early‐onset AD (EOAD; <65 years) is scarce.Methods: We included 62 EOAD patients and 44 healthy controls (HCs) with core AD cerebrospinal fluid (CSF) biomarkers, neurofilament light chain levels, neuropsychological assessment, and 3‐T magnetic resonance imaging. We measured cortical thickness (CTh) and hippocampal subfield volumes (HpS) using FreeSurfer. Adjusted linear models were used to analyze sex‐differences and the relationship between atrophy and cognition.Results: Compared to same‐sex HCs, female EOAD subjects showed greater cognitive impairment and broader atrophy burden than male EOAD subjects. In a direct female‐EOAD versus male‐EOAD comparison, there were slight differences in temporal CTh, with no differences in cognition or HpS. CSF tau levels were higher in female EOAD than in male EOAD subjects. Greater atrophy was associated with worse cognition in female EOAD subjects.Conclusions: At diagnosis, there are sex differences in the pattern of cognitive impairment, atrophy burden, and CSF tau in EOAD, suggesting there is an influence of sex on pathology spreading and susceptibility to the disease in EOAD.
- 12 August 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6411-6428
Differential Gene Expression in Sporadic and Genetic Forms of Alzheimer’s Disease and Frontotemporal Dementia in Brain Tissue and Lymphoblastoid Cell Lines
Sporadic early-onset Alzheimer’s disease (EOAD) and autosomal dominant Alzheimer’s disease (ADAD) provide the opportunity to investigate the physiopathological mechanisms in the absence of aging, present in late-onset forms. Frontotemporal dementia (FTD) causes early-onset dementia associated to tau or TDP43 protein deposits. A 15% of FTD cases are caused by mutations in C9orf72, GRN, or MAPT genes. Lymphoblastoid cell lines (LCLs) have been proposed as an alternative to brain tissue for studying earlier phases of neurodegenerative diseases. The aim of this study is to investigate the expression profile in EOAD, ADAD, and sporadic and genetic FTD (sFTD and gFTD, respectively), using brain tissue and LCLs. Sixty subjects of the following groups were included: EOAD, ADAD, sFTD, gFTD, and controls. Gene expression was analyzed with Clariom D microarray (Affymetrix). Brain tissue pairwise comparisons revealed six common differentially expressed genes (DEG) for all the patients’ groups compared with controls: RGS20, WIF1, HSPB1, EMP3, S100A11 and GFAP. Common up-regulated biological pathways were identified both in brain and LCLs (including inflammation and glial cell differentiation), while down-regulated pathways were detected mainly in brain tissue (including synaptic signaling, metabolism and mitochondrial dysfunction). CD163, ADAMTS9 and LIN7A gene expression disruption was validated by qPCR in brain tissue and NrCAM in LCLs in their respective group comparisons. In conclusion, our study highlights neuroinflammation, metabolism and synaptic signaling disturbances as common altered pathways in different AD and FTD forms. The use of LCLs might be appropriate for studying early immune system and inflammation, and some neural features in neurodegenerative dementias.
- 12 August 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6411-6428
Differential Gene Expression in Sporadic and Genetic Forms of Alzheimer’s Disease and Frontotemporal Dementia in Brain Tissue and Lymphoblastoid Cell Lines
Sporadic early-onset Alzheimer’s disease (EOAD) and autosomal dominant Alzheimer’s disease (ADAD) provide the opportunity to investigate the physiopathological mechanisms in the absence of aging, present in late-onset forms. Frontotemporal dementia (FTD) causes early-onset dementia associated to tau or TDP43 protein deposits. A 15% of FTD cases are caused by mutations in C9orf72, GRN, or MAPT genes. Lymphoblastoid cell lines (LCLs) have been proposed as an alternative to brain tissue for studying earlier phases of neurodegenerative diseases. The aim of this study is to investigate the expression profile in EOAD, ADAD, and sporadic and genetic FTD (sFTD and gFTD, respectively), using brain tissue and LCLs. Sixty subjects of the following groups were included: EOAD, ADAD, sFTD, gFTD, and controls. Gene expression was analyzed with Clariom D microarray (Affymetrix). Brain tissue pairwise comparisons revealed six common differentially expressed genes (DEG) for all the patients’ groups compared with controls: RGS20, WIF1, HSPB1, EMP3, S100A11 and GFAP. Common up-regulated biological pathways were identified both in brain and LCLs (including inflammation and glial cell differentiation), while down-regulated pathways were detected mainly in brain tissue (including synaptic signaling, metabolism and mitochondrial dysfunction). CD163, ADAMTS9 and LIN7A gene expression disruption was validated by qPCR in brain tissue and NrCAM in LCLs in their respective group comparisons. In conclusion, our study highlights neuroinflammation, metabolism and synaptic signaling disturbances as common altered pathways in different AD and FTD forms. The use of LCLs might be appropriate for studying early immune system and inflammation, and some neural features in neurodegenerative dementias.
- Open Access
- 16 January 2020
- Published by Wiley in Human Brain Mapping
- Vol. 41 (8) , 2004-2013
Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures
Prior studies have described distinct patterns of brain gray matter and white matter alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to investigate the relationship between early‐onset AD (EOAD) and FTLD structural alterations and CSF biomarker levels. We included 138 subjects (64 EOAD, 26 FTLD, and 48 controls), all of them with a 3T MRI brain scan and CSF biomarkers available (the 42 amino acid‐long form of the amyloid‐beta protein [Aβ42], total‐tau protein [T‐tau], neurofilament light chain [NfL], neurogranin [Ng], and 14‐3‐3 levels). We used FreeSurfer and FSL to obtain cortical thickness (CTh) and fraction anisotropy (FA) maps. We studied group differences in CTh and FA and described the “AD signature” and “FTLD signature.” We tested multiple regression models to find which CSF‐biomarkers better explained each disease neuroimaging signature. CTh and FA maps corresponding to the AD and FTLD signatures were in accordance with previous literature. Multiple regression analyses showed that the biomarkers that better explained CTh values within the AD signature were Aβ and 14‐3‐3; whereas NfL and 14‐3‐3 levels explained CTh values within the FTLD signature. Similarly, NfL levels explained FA values in the FTLD signature. Ng levels were not predictive in any of the models. Biochemical markers contribute differently to structural (CTh and FA) changes typical of AD and FTLD.
- 16 January 2020
- Published by Wiley in Human Brain Mapping
- Vol. 41 (8) , 2004-2013
Open AccessContribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures
Prior studies have described distinct patterns of brain gray matter and white matter alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to investigate the relationship between early‐onset AD (EOAD) and FTLD structural alterations and CSF biomarker levels. We included 138 subjects (64 EOAD, 26 FTLD, and 48 controls), all of them with a 3T MRI brain scan and CSF biomarkers available (the 42 amino acid‐long form of the amyloid‐beta protein [Aβ42], total‐tau protein [T‐tau], neurofilament light chain [NfL], neurogranin [Ng], and 14‐3‐3 levels). We used FreeSurfer and FSL to obtain cortical thickness (CTh) and fraction anisotropy (FA) maps. We studied group differences in CTh and FA and described the “AD signature” and “FTLD signature.” We tested multiple regression models to find which CSF‐biomarkers better explained each disease neuroimaging signature. CTh and FA maps corresponding to the AD and FTLD signatures were in accordance with previous literature. Multiple regression analyses showed that the biomarkers that better explained CTh values within the AD signature were Aβ and 14‐3‐3; whereas NfL and 14‐3‐3 levels explained CTh values within the FTLD signature. Similarly, NfL levels explained FA values in the FTLD signature. Ng levels were not predictive in any of the models. Biochemical markers contribute differently to structural (CTh and FA) changes typical of AD and FTLD.